Stonepine Capital Management LLC Has $1.52 Million Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Stonepine Capital Management LLC lessened its holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 19.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 999,790 shares of the company’s stock after selling 239,409 shares during the period. Milestone Pharmaceuticals accounts for about 1.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Stonepine Capital Management LLC’s holdings in Milestone Pharmaceuticals were worth $1,520,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. BML Capital Management LLC raised its holdings in Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after acquiring an additional 33,196 shares during the period. Atria Investments Inc raised its holdings in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the period. Valeo Financial Advisors LLC raised its holdings in Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after acquiring an additional 10,000 shares during the period. Finally, Lion Point Capital LP raised its holdings in Milestone Pharmaceuticals by 1.7% in the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after acquiring an additional 40,000 shares during the period. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Trading Down 0.3 %

MIST stock traded down $0.01 during trading hours on Wednesday, reaching $1.85. The stock had a trading volume of 63,349 shares, compared to its average volume of 234,242. The stock has a 50-day simple moving average of $1.60 and a 200 day simple moving average of $1.52. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $3.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Equities research analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MIST has been the topic of several research reports. Rodman & Renshaw began coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 22nd. They set a “buy” rating and a $9.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Monday, October 14th.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.